<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574960</url>
  </required_header>
  <id_info>
    <org_study_id>20-5149</org_study_id>
    <nct_id>NCT04574960</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)</brief_title>
  <acronym>NAUTICAL</acronym>
  <official_title>Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bladder Cancer Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the&#xD;
      tube that drains the kidney). This type of cancer is rare and as a result, there are only a&#xD;
      few studies that have looked at it.&#xD;
&#xD;
      Standard of care for UTUC would be surgery followed by chemotherapy (adjuvant chemotherapy).&#xD;
      However, we know from studies that have looked at cancer of the lining of the bladder, which&#xD;
      is a similar cancer in many ways, that treating people with chemotherapy before surgery&#xD;
      (neoadjuvant chemotherapy) can lead to longer survival compared to the standard of care.&#xD;
      There are no studies to show this in UTUC. Neoadjuvant chemotherapy is thought to help&#xD;
      improve survival by treating any cancer that may have spread from the original tumour but&#xD;
      that is not visible yet on scans. This study would be the first clinical trial in Canada to&#xD;
      evaluate the use of chemotherapy before surgery in this disease setting.&#xD;
&#xD;
      Since UTUC is rare, the purpose of this study is to determine if it is possible to enrol&#xD;
      enough patients to a trial looking at the use of chemotherapy before surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of enrolling cT1-4N0 M0 UTUC patients in a randomized trial of neoadjuvant chemotherapy versus standard of care by assessing pilot trial recruitment rates</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>36 months</time_frame>
    <description>DFS is defined as the time from randomization to development of intravesical recurrence, contralateral upper tract recurrence or distant metastasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of complete pathologic response</measure>
    <time_frame>36 months</time_frame>
    <description>Complete pathologic response is defined as pT0 N0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Site-specific enrolment rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients approached per site per month</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients randomized per site per month</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Bladder Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemotherapy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Chemotherapy Arm (Standard of Care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy.&#xD;
Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin.&#xD;
Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles.&#xD;
Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle</description>
    <arm_group_label>Adjuvant Chemotherapy Arm (Standard of Care)</arm_group_label>
    <arm_group_label>Neoadjuvant Chemotherapy Arm</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle</description>
    <arm_group_label>Adjuvant Chemotherapy Arm (Standard of Care)</arm_group_label>
    <arm_group_label>Neoadjuvant Chemotherapy Arm</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle</description>
    <arm_group_label>Adjuvant Chemotherapy Arm (Standard of Care)</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed radiographically visible (CT or MRI) cT1-4 N0 M0 with positive&#xD;
             selective urinary cytology or endoscopic biopsy for high grade urothelial cell&#xD;
             carcinoma&#xD;
&#xD;
          -  Age ≥18 years of age&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score 0-1&#xD;
&#xD;
          -  Medically appropriate candidate for radical nephroureterectomy or ureterectomy as per&#xD;
             participating site attending urologic oncologist&#xD;
&#xD;
          -  Medically appropriate candidate for cisplatin-based chemotherapy as per participating&#xD;
             site attending medical oncologist&#xD;
&#xD;
          -  Adequate organ system function defined as follows: absolute neutrophil count ≥&#xD;
             1500/mm3, platelets ≥ 100,00/mm3, hemoglobin ≥ 90 g/L, ALT and AST &lt; 2.5 x upper limit&#xD;
             of normal, electrolytes (Na, K, Mg, Ca): within normal limits, GFR ≥ 60 mL/min&#xD;
&#xD;
        Patients who are randomized to the adjuvant chemotherapy will be reassessed for suitability&#xD;
        to receive adjuvant chemotherapy after definitive surgery (nephroureterectomy or&#xD;
        ureterectomy) based on the following criteria:&#xD;
&#xD;
          -  pT2-4 N0-3 M0 or pT any N1-3 M0 with predominant urothelial component&#xD;
&#xD;
          -  ECOG score 0-2&#xD;
&#xD;
          -  Medically appropriate candidate for platin-based chemotherapy as per participating&#xD;
             site attending medical oncologist&#xD;
&#xD;
          -  Adequate organ system function defined as follows: absolute neutrophil count ≥&#xD;
             1500/mm3, platelets ≥ 100,00/mm3, hemoglobin ≥ 90 g/L, ALT and AST &lt; 2.5 x upper limit&#xD;
             of normal, electrolytes (Na, K, Mg, Ca): within normal limits, GFR ≥ 30 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Radiographically visible nodal disease&#xD;
&#xD;
          -  Concurrent muscle-invasive bladder cancer (non-muscle invasive bladder cancer is&#xD;
             acceptable)&#xD;
&#xD;
          -  Solitary kidney&#xD;
&#xD;
          -  Other cancer diagnosis or systemic chemotherapy use within 2 years of study enrollment&#xD;
             (prior bladder cancer and intravesical therapy allowed)&#xD;
&#xD;
          -  Concomitant diseases that are a formal exclusion to cisplatin chemotherapy (deafness,&#xD;
             ≥ grade II neuropathy, serious active infection)&#xD;
&#xD;
          -  Concomitant use of any other investigational drugs&#xD;
&#xD;
          -  Pregnancy or breast feeding (you must remain on contraception, not father a child or&#xD;
             donate sperm while receiving gemcitabine/cisplatin and for 6 months following the last&#xD;
             dose)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Girish Kulkarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network - Princess Margaret Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lena Sundaram</last_name>
    <phone>(416) 634-8219</phone>
    <email>lena.sundaram2@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha Fung</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>3897</phone_ext>
    <email>samantha.fung2@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cheung</last_name>
      <phone>(437) 335-2949</phone>
      <email>sarah.cheung@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Aisha Egal</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>3951</phone_ext>
      <email>aisha.egal@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Girish Kulkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Upper tract urothelial carcinoma</keyword>
  <keyword>UTUC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

